Log In
BCIQ
Print this Print this
 

Carbavance, meropenem/vaborbactam

  Manage Alerts
Collapse Summary General Information
Company The Medicines Co.
DescriptionCombination of vaborbactam, a boron-containing beta lactamase (LACTB) inhibitor, and meropenem, a carbapenem antibiotic
Molecular Target Beta lactamase (LACTB)
Mechanism of ActionBeta lactamase inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$474.0M

$140.0M

$334.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/09/2013

$474.0M

$140.0M

$334.0M

Get a free BioCentury trial today